David Ross, MBBS, PhD, FRACP, FRCPA, Royal Adelaide Hospital and Institute, Adelaide, Australia, discusses the identification of granulocytes and T-cells as biomarkers for disease relapse and response prediction following discontinuation of tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.